AVTR Avantor, Inc.
Laboratory Analytical Instruments · NYSE · SEC CIK 1722482 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY0.9%
TTM net income YoY510.2%
TTM EPS YoY484.6%
Revenue 3-yr CAGR-1.9%
Net income 3-yr CAGR-2.5%
Margins
Gross margin31.6%
Operating margin7.3%
Net margin5.1%
FCF margin6.6%
EBITDA margin13.7%
Returns
ROE5.9%
ROA2.9%
ROIC (approx.)5.3%
Asset turnover0.57x
Leverage & solvency
Liabilities / assets49.8%
Debt / equity0.63x
Current ratio1.89x
Interest coverage3.00x
Cash quality & payout
Operating cash flow / net income1.73x
Accruals ratio-2.1%
Payout ratio—
Capex / revenue2.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.70B | $1.69B | $1.58B | $1.66B | $1.62B | $1.68B | $1.58B | $1.69B |
| Cost of revenue | $1.16B | $1.16B | $1.08B | $1.14B | $1.10B | $1.13B | $1.05B | $1.12B |
| Gross profit | $534.80M | $537.00M | $500.70M | $523.90M | $526.50M | $554.10M | $534.90M | $562.90M |
| SG&A expense | $395.30M | $415.20M | $401.20M | $392.40M | $390.30M | $425.30M | $387.50M | $371.40M |
| Operating income | $139.50M | $121.80M | $99.50M | $126.40M | -$648.80M | $128.80M | $147.40M | $638.10M |
| Interest expense | $39.90M | $39.40M | $42.90M | $40.00M | $44.20M | $43.40M | $42.20M | $44.90M |
| Pretax income | $98.00M | $81.20M | $55.50M | $80.80M | -$689.50M | $81.70M | $85.70M | $584.20M |
| Income tax | -$105.40M | $43.10M | $12.20M | $28.40M | $22.30M | $17.00M | $21.20M | $83.80M |
| Net income | $203.40M | $38.10M | $43.30M | $52.40M | -$711.80M | $64.70M | $64.50M | $500.40M |
| EBITDA | $244.80M | $227.40M | $204.50M | $229.70M | -$544.30M | $231.50M | $247.10M | $739.00M |
| EPS (basic) | 0.30 | 0.06 | 0.06 | — | -1.04 | 0.09 | 0.09 | — |
| EPS (diluted) | 0.30 | 0.06 | 0.06 | — | -1.04 | 0.09 | 0.09 | — |
| Weighted avg. shares (diluted) | 680.90M | 677.20M | 676.80M | — | 681.70M | 681.80M | 682.40M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $464.30M | $306.80M | $279.30M | $365.40M | $254.70M | $452.20M | $318.50M | $264.70M |
| Receivables | $1.12B | $1.14B | $1.10B | $1.07B | $1.08B | $1.15B | $1.10B | $1.03B |
| Inventory | $854.80M | $828.70M | $810.30M | $818.20M | $795.50M | $779.80M | $750.10M | $731.50M |
| Current assets | $2.59B | $2.46B | $2.40B | $2.45B | $2.26B | $2.51B | $2.28B | $2.15B |
| PP&E, net | $778.90M | $772.10M | $766.20M | $766.80M | $761.60M | $759.00M | $736.30M | $708.10M |
| Goodwill | $4.93B | $4.94B | $4.95B | $4.99B | $4.98B | $5.76B | $5.61B | $5.54B |
| Intangibles | $2.84B | $2.92B | $3.01B | $3.10B | $3.17B | $3.26B | $3.24B | $3.27B |
| Total assets | $11.63B | $11.60B | $11.66B | $11.79B | $11.68B | $12.78B | $12.33B | $12.11B |
| Current liabilities | $1.37B | $1.38B | $1.37B | $1.38B | $1.52B | $2.58B | $2.03B | $2.01B |
| Short-term debt | $35.00M | $37.00M | $37.00M | $30.80M | $219.80M | $1.25B | $827.50M | $821.10M |
| Long-term debt | $3.65B | $3.66B | $3.78B | $3.92B | $3.64B | $2.99B | $3.28B | $3.23B |
| Total debt | $3.68B | $3.70B | $3.82B | $3.95B | $3.86B | $4.24B | $4.11B | $4.06B |
| Total liabilities | $5.79B | $5.97B | $6.07B | $6.23B | $6.11B | $6.49B | $6.23B | $6.16B |
| Shareholders' equity | $5.84B | $5.63B | $5.59B | $5.57B | $5.57B | $6.29B | $6.10B | $5.96B |
| Net debt | $3.22B | $3.39B | $3.54B | $3.58B | $3.60B | $3.79B | $3.79B | $3.79B |
| Shares outstanding | — | — | 682.90M | 682.00M | 681.90M | 681.60M | 681.50M | 680.80M |
| Cash flow statement | ||||||||
| Operating cash flow | $195.10M | $178.20M | $58.70M | $152.70M | $207.40M | $154.40M | $109.30M | $173.30M |
| Capital expenditure | $38.90M | $37.60M | $33.50M | $35.50M | $35.70M | $29.60M | $28.00M | $27.50M |
| Free cash flow | $156.20M | $140.60M | $25.20M | $117.20M | $171.70M | $124.80M | $81.30M | $145.80M |
| Investing cash flow | -$38.50M | -$37.30M | -$32.70M | -$39.70M | -$33.30M | -$28.60M | -$28.90M | $558.50M |
| Financing cash flow | $1.80M | -$112.40M | -$107.20M | $700,000 | -$369.60M | -$6.90M | -$33.60M | -$755.30M |
| Depreciation & amortization | $105.30M | $105.60M | $105.00M | $103.30M | $104.50M | $102.70M | $99.70M | $100.90M |
| Stock-based compensation | $12.50M | $15.40M | $8.60M | $11.30M | $7.30M | $15.50M | $12.40M | $11.10M |
Free plan shows the latest 8 periods; Pro shows all 35 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.